Adelmidrol ameliorates liver ischemia-reperfusion injury through activating Nrf2 signaling pathway
Laboratory studyOther animalsWith adelmidrol (a PEA analogue, tested alone)
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with liver ischaemia-reperfusion injury and AML12 liver cells under hypoxia-reoxygenation
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Serum ALT and AST, liver histology, oxidative stress markers, inflammatory cytokine mRNA, neutrophil staining, and apoptosis proteins
What the authors reported
Adelmidrol reduced liver ischaemia-reperfusion injury in mice. Pretreatment raised AML12 cell viability and reduced apoptosis, inflammatory injury and oxidative stress. The Nrf2 inhibitor ML385 reversed the protection, which the authors attribute to Nrf2 activation.
Limits of this study
A mouse and cell study; it cannot show effect in people. Adelmidrol is an analogue, not palmitoylethanolamide. No doses or group sizes are given in the abstract. The authors declare no competing interests.
Source
PubMed 38110141 · doi:10.1016/j.ejphar.2023.176224
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.